New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
Go back to New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my| Johnson & Johnson (NYSE: JNJ) | Delayed: 231.29 +2.90 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.39 | 52 Week High | $126.07 | |||
| Open | $228.95 | 52 Week Low | $94.28 | |||
| Day High | $231.45 | P/E | 48.09 | |||
| Day Low | $227.50 | EPS | $4.81 | |||
| Volume | 8,518,208 | |||||
